Skip to main content

Neurofibromatosis Type 1 clinical trials at UCSD
1 in progress, 0 open to new patients

  • Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas

    Sorry, not currently recruiting here

    This is a phase II open label study that will evaluate children ≥ 1 year of age and adults with neurofibromatosis type 1 (NF1) and plexiform neurofibromas treated with the MEK inhibitor, binimetinib. The primary objective is to determine if there is an adequate level of disease responsiveness to binimetinib in children and adults with NF1 and inoperable plexiform neurofibromas. The objective response to binimetinib is defined as ≥ 20% decrease in tumor volume reduction by 12 courses.

    San Diego, California and other locations

Last updated: